# US Benign Prostatic Hyperplasia Treatment Market

> US Benign Prostatic Hyperplasia Treatment Market Research Report: Size, Share, Trend Analysis By Therapeutic Class (Alpha Blockers, 5- Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others) and By Therapy (Mono Drug Therapy, Combination Drug Therapy) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.32%
- **2024:** $ 2,632.61 Million
- **2025:** $ 2,772.66 Million
- **2035:** $ 4,657.5 Million
- **Key Players:** Astellas Pharma (JP), Boehringer Ingelheim (DE), Eli Lilly and Company (US), GlaxoSmithKline (GB), Johnson & Johnson (US), Merck & Co. (US), Pfizer (US), Sanofi (FR), Teva Pharmaceutical Industries (IL)

**Report ID:** MRFR/HC/14339-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-benign-prostatic-hyperplasia-treatment-market-15866

---

## Market Summary

## **US Benign Prostatic Hyperplasia Treatment Market Overview**

As per MRFR analysis, the US Benign Prostatic Hyperplasia Treatment Market Size was estimated at 2.48 (USD Billion) in 2023. The US Benign Prostatic Hyperplasia Treatment Market Industry is expected to grow from 2.75(USD Billion) in 2024 to 5.1 (USD Billion) by 2035. The US Benign Prostatic Hyperplasia Treatment Market CAGR (growth rate) is expected to be around 5.776% during the forecast period (2025 - 2035).

### **Key US Benign Prostatic Hyperplasia Treatment Market Trends Highlighted**

The US Benign Prostatic Hyperplasia (BPH) treatment market is primarily driven by the increasing aging population, as men over the age of 50 commonly experience this condition. The rise in lifestyle-related factors, such as obesity and sedentary habits, also contributes significantly to the growing incidence of BPH. Healthcare providers are focusing on minimally invasive treatment options, which have gained popularity due to their effectiveness and reduced recovery times compared to traditional surgical procedures. As patients increasingly seek less invasive alternatives, products such as laser therapy and prostatic stenting are becoming more prevalent in treatment hospitals across the US.

In terms of opportunities, the US market shows significant potential for advancements in pharmacological solutions targeting BPH. The development and approval of new drug classes could provide effective management for patients and address unmet medical needs for those who are not candidates for surgical intervention. Moreover, there is an opportunity for patient education and awareness initiatives that could encourage early diagnosis and treatment, which may alleviate symptoms and improve quality of life for many men suffering from this condition.

Recent trends indicate a shift towards telemedicine and digital health solutions in the US healthcare system. With the COVID-19 pandemic accelerating the adoption of remote healthcare, patients are now able to consult with urologists and specialists from the comfort of their homes. This trend is expected to remain prevalent as it offers convenience to patients and can lead to increased adherence to treatment plans. Additionally, ongoing research and clinical trials focused on innovative therapies continue to evolve, promising robust advancements in the management of BPH in the US.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Benign Prostatic Hyperplasia Treatment Market Drivers**

### **Increasing Prevalence of Benign Prostatic Hyperplasia**

The prevalence of Benign Prostatic Hyperplasia (BPH) significantly contributes to the growth of the US Benign Prostatic Hyperplasia Treatment Market Industry. According to the National Institutes of Health, nearly 50% of men aged 51 to 60 and about 90% of men aged 80 and older are affected by BPH. With the aging population in the United States, it is estimated that by 2030, the population of men aged 65 and older will reach 78 million. This demographic shift will lead to an increasing demand for effective treatment options for BPH, thereby driving market growth.

Established organizations such as the American Urological Association consistently highlight the need for advancements in BPH treatments, further emphasizing this trend. The ongoing Research and Development initiatives by pharmaceutical firms and medical device companies to innovate new treatment procedures and drugs will also be essential in meeting this rising demand, creating opportunities in the US Benign Prostatic Hyperplasia Treatment Market Industry.

### **Advancements in Minimally Invasive Treatments**

Minimally invasive treatment procedures for Benign Prostatic Hyperplasia have gained significant traction in the US, as they offer quicker recovery times and reduced hospital stays compared to traditional surgeries. The Urology Care Foundation reports that these advances have resulted in increased patient satisfaction and lower healthcare costs. Prominent organizations such as Medtronic and Boston Scientific are actively developing and improving technologies like laser therapy and prostatic artery embolization.

As awareness of these options grows among healthcare providers and patients, the US Benign Prostatic Hyperplasia Treatment Market Industry is expected to see considerable expansion.

### **Growing Awareness and Educational Initiatives**

There is a growing movement to improve awareness around Benign Prostatic Hyperplasia, which in turn fuels the US Benign Prostatic Hyperplasia Treatment Market Industry. Campaigns led by organizations like the American Urological Association and the Prostate Cancer Foundation are providing critical educational resources about BPH and available treatment options. According to surveys, approximately 60% of men do not discuss BPH symptoms with their healthcare providers, suggesting a significant gap in knowledge.

Thus, as these organizations become more active in educating the public, it is likely that more patients will seek treatment, driving market growth.

## **US Benign Prostatic Hyperplasia Treatment Market Segment Insights**

### **Benign Prostatic Hyperplasia Treatment Market Therapeutic Class Insights**

The US Benign Prostatic Hyperplasia Treatment Market encompasses several therapeutic classes that address this prevalent condition affecting a significant portion of the male population. Among these classes, Alpha Blockers play a pivotal role in providing symptomatic relief by relaxing the muscles in the prostate and bladder neck, thereby improving urine flow. They are often favored due to their rapid onset of action and are invaluable in the clinical management of benign prostatic hyperplasia symptoms.

5-Alpha Reductase Inhibitors, on the other hand, help reduce the prostate size over time by inhibiting hormonal activity, and therefore, they are instrumental in managing the condition's progression. This class focuses on targeting the underlying hormonal factors that contribute to prostate enlargement. Phosphodiesterase-5 Inhibitors have gained recognition not just for erectile dysfunction, but also for aiding in the management of urinary symptoms due to benign prostatic hyperplasia. Their dual action presents a synergistic approach to treating men with concurrent conditions.

Additionally, other therapeutic options include herbal remedies and combination therapies, which offer various alternatives catering to diverse patient preferences and medical histories. The dynamics within the US Benign Prostatic Hyperplasia Treatment Market illustrate a trend towards personalized medicine, as ongoing research aims to unveil treatment regimens tailored to individual patient profiles, thereby enhancing therapeutic outcomes. The evolving landscape is also characterized by increasing awareness among the aging population about prostate health, which propels the demand for effective treatment solutions.

Factors contributing to the growth of the therapeutic class segment include a rising geriatric demographic, advancements in drug formulation, and improved access to healthcare services. Consequently, healthcare providers are likely to witness a gradual shift toward more integrative treatment strategies, which may effectively address the multifactorial aspects of benign prostatic hyperplasia. Therefore, the therapeutic class segment is marked by its robust potential for innovation and adaptation to changing patient needs, thereby offering significant opportunities for growth within the US Benign Prostatic Hyperplasia Treatment Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Benign Prostatic Hyperplasia Treatment Market Therapy Insights**

The Therapy segment within the US [Benign Prostatic Hyperplasia Treatment](../../../reports/benign-prostatic-hyperplasia-treatment-market-11838) Market encompasses various treatment approaches essential for managing this condition, which affects a significant portion of the male population, particularly those aged 50 and older. Mono Drug Therapy remains a relevant treatment option by utilizing a single medication to alleviate symptoms effectively. This method is advantageous due to its straightforward approach, appealing to patients seeking a less complex regimen.

On the other hand, Combination Drug Therapy has gained traction as it integrates multiple therapeutic agents, leading to enhanced efficacy and symptom relief. The use of combination therapies is critical as it addresses the diverse symptoms experienced by patients, catering to individual needs and improving treatment outcomes. This growing trend towards personalized medicine highlights the importance of tailored treatment approaches in the US, aligning with healthcare directives aimed at improving patient quality of life.

Furthermore, advances in drug formulations and increasing awareness about benign prostatic hyperplasia are driving the demand for these therapies, reflecting a broader shift in the US healthcare industry towards more effective and patient-centric solutions. Overall, the therapy segment is pivotal as it underlies the strategies employed to improve the lives of those affected by benign prostatic hyperplasia, showcasing both ongoing challenges and tremendous opportunities in the market.

## **US Benign Prostatic Hyperplasia Treatment Market Key Players and Competitive Insights**

The US Benign Prostatic Hyperplasia Treatment Market is characterized by a dynamic and competitive landscape driven by increasing prevalence rates, advanced treatment options, and a growing awareness of the condition among healthcare providers and patients. Innovations in pharmaceuticals and minimally invasive surgical procedures have transformed the therapeutic approaches for benign prostatic hyperplasia (BPH), leading to enhanced patient outcomes and quality of life. Key players in this market are focusing on research and development to deliver effective therapies, while also exploring collaborations and strategic partnerships to expand their product portfolios and market reach.

The competitive environment is marked by a mix of established pharmaceutical companies and emerging players, each vying for market share through differentiation and agility in response to changing market needs.

Merck and Co has established a strong presence in the US Benign Prostatic Hyperplasia Treatment Market, powered by its commitment to research and the development of novel treatment options. The company leverages its robust pipeline to offer treatments that not only alleviate symptoms of BPH but also address underlying causes. Merck's efforts in clinical trials and collaborations with healthcare institutions help to solidify its standing and enhance its credibility within the medical community. The reliability and efficiency of its products have garnered favorable perceptions among healthcare professionals and patients alike, contributing positively to the company's market growth.

Moreover, Merck's extensive distribution and marketing networks enable it to effectively reach a broader audience, ensuring that its treatments are accessible to patients in various healthcare settings across the United States.

Novartis has made significant inroads into the US Benign Prostatic Hyperplasia Treatment Market through strategic investments and innovative therapies tailored to manage the condition effectively. The company’s key products in this space focus on addressing the multifaceted aspects of BPH, including symptom relief and long-term management strategies. Novartis is acknowledged for its contributions to clinical research, which enhances its credibility as a leading player in the field. The organization is also recognized for its strategic mergers and acquisitions, bolstering its capabilities and expanding its product portfolio within the US market.

With a focus on patient-centric approaches, Novartis successfully aligns its offerings to meet the needs of a diverse patient population. This flexibility, combined with a formidable research infrastructure, underscores the company’s strengths and its ongoing dedication to making a meaningful impact in the treatment landscape for benign prostatic hyperplasia.

### **Key Companies in the US Benign Prostatic Hyperplasia Treatment Market Include**

## **US Benign Prostatic Hyperplasia Treatment Market Industry Developments**

Recent developments in the US Benign Prostatic Hyperplasia Treatment Market have shown significant activity among key players, with companies like Merck and Co., Novartis, and Eli Lilly advancing their treatment options. In September 2023, Bausch Health announced the launch of a new formulation designed to improve patient outcomes, which is expected to enhance their market share. The growing prevalence of BPH in the aging US population has driven demand, prompting Boehringer Ingelheim and Ferring Pharmaceuticals to invest in Research and Development for innovative therapies.

Furthermore, in August 2023, AbbVie completed the acquisition of a smaller biotech company focused on novel BPH treatments, aiming to expand its product portfolio substantially. Companies such as Astellas Pharma and Sanofi continue to explore strategic partnerships to enhance their treatment offerings. Over the past few years, there has been a consistent upward trend in the market valuation of companies like Johnson and Johnson and Teva Pharmaceuticals, contributing positively to the overall market dynamics. The US government has also identified BPH as a priority area for research funding, underlining its significance in public health initiatives.

The ongoing advancements and investments clearly indicate a vigorous market evolution in the US.

## **US Benign Prostatic Hyperplasia Treatment Market Segmentation Insights**

### **Benign Prostatic Hyperplasia Treatment Market Therapeutic Class Outlook**

### **Benign Prostatic Hyperplasia Treatment Market Therapy Outlook**

## Market Drivers

### Rising Awareness and Education

Increased awareness and education regarding benign prostatic hyperplasia are driving growth in the benign prostatic-hyperplasia-treatment market. Campaigns aimed at educating men about BPH symptoms and treatment options have led to a greater understanding of the condition. This heightened awareness encourages men to seek medical advice earlier, resulting in timely interventions. Healthcare providers are increasingly focusing on patient education, which is essential for improving treatment adherence and outcomes. As more men become informed about the potential complications of untreated BPH, the demand for effective treatment options is likely to rise. This trend is expected to positively impact the benign prostatic-hyperplasia-treatment market, as more patients actively pursue solutions to manage their symptoms.

### Increasing Healthcare Expenditure

The benign prostatic-hyperplasia-treatment market is also influenced by rising healthcare expenditure in the United States. As healthcare spending continues to grow, patients are more likely to seek medical attention for conditions like BPH. The U.S. healthcare expenditure is projected to reach approximately $6 trillion by 2027, which may facilitate access to advanced treatment options for BPH. Increased funding for research and development in urology is likely to lead to the introduction of novel therapies and improved treatment protocols. This financial commitment to healthcare is expected to enhance the benign prostatic-hyperplasia-treatment market, as more resources become available for patient care and innovative treatment solutions.

### Advancements in Medical Technology

Technological advancements play a crucial role in shaping the benign prostatic-hyperplasia-treatment market. Innovations in minimally invasive surgical techniques, such as laser therapy and transurethral resection of the prostate (TURP), have improved patient outcomes and reduced recovery times. These advancements not only enhance the efficacy of treatments but also attract more patients seeking effective solutions for BPH. The market is witnessing a growing adoption of robotic-assisted surgeries, which offer precision and reduced complications. Furthermore, the integration of digital health technologies, including telehealth platforms, is facilitating better patient management and follow-up care. As these technologies continue to evolve, they are likely to contribute to the expansion of the benign prostatic-hyperplasia-treatment market, making treatments more accessible and efficient.

### Aging Population and Increased Incidence

The benign prostatic-hyperplasia-treatment market is significantly influenced by the aging population in the United States. As men age, the likelihood of developing benign prostatic hyperplasia (BPH) increases, with studies indicating that approximately 50% of men aged 50 and older experience some degree of BPH. This demographic shift is expected to drive demand for treatment options, as the population aged 65 and older is projected to reach 80 million by 2040. Consequently, healthcare providers are likely to see a surge in patients seeking interventions for BPH, thereby propelling growth in the benign prostatic-hyperplasia-treatment market. The increasing prevalence of BPH among older men necessitates a variety of treatment modalities, including medications and surgical options, further expanding the market landscape.

### Regulatory Support and Approval of New Treatments

Regulatory support for the approval of new treatments is a vital driver of the benign prostatic-hyperplasia-treatment market. The U.S. Food and Drug Administration (FDA) plays a crucial role in evaluating and approving new therapies for BPH. Recent approvals of novel medications and devices have expanded the treatment landscape, providing patients with more options. The FDA's streamlined processes for innovative therapies may encourage pharmaceutical companies to invest in research and development for BPH treatments. As new therapies enter the market, competition is likely to increase, potentially leading to more effective and affordable treatment options for patients. This regulatory environment is expected to foster growth in the benign prostatic-hyperplasia-treatment market.

## Future Outlook

The [Benign Prostatic Hyperplasia Treatment Market](https://www.marketresearchfuture.com/reports/benign-prostatic-hyperplasia-treatment-market-11838) is projected to grow at a 5.32% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring Investment in minimally invasive surgical technologies Expansion of personalized medicine approaches for tailored treatments

By 2035, the market is expected to achieve robust growth, reflecting evolving treatment paradigms.

## Segment Insights

### By Therapeutic Class: Alpha Blockers (Largest) vs. 5- Alpha Reductase Inhibitors (Fastest-Growing)

In the US benign prostatic-hyperplasia-treatment market, the therapeutic class segment is predominantly led by Alpha Blockers, which hold a significant market share owing to their established efficacy and favorable side effect profile. Following closely, 5- Alpha Reductase Inhibitors are gaining traction, primarily due to their prolonged therapeutic benefits, thereby capturing a noteworthy segment of the market. With emerging therapies and increased patient awareness, the competition among therapeutic classes is intensifying.

The growth trends within this segment are fueled by innovative drug formulations and expanding indications for existing therapies. Additionally, the rising prevalence of benign prostatic hyperplasia (BPH) combined with an aging demographic is expected to drive demand for these treatment options. Healthcare providers are increasingly recommending a combination therapy approach, which is likely to bolster the growth of both Alpha Blockers and 5- Alpha Reductase Inhibitors, positioning them prominently within the market.

Alpha Blockers (Dominant) vs. 5- Alpha Reductase Inhibitors (Emerging)

Alpha Blockers are widely recognized as the dominant therapeutic class in the treatment landscape, primarily due to their effective symptom relief for patients suffering from BPH. They act rapidly to relax the muscles in the prostate and bladder neck, leading to improved urinary flow. Conversely, 5- Alpha Reductase Inhibitors represent an emerging segment that inhibits the hormonal activity leading to prostate growth. Although they have a delayed onset of action, they provide lasting benefits by reducing the size of the prostate over time. This contrast between immediate relief (Alpha Blockers) and long-term management (5- Alpha Reductase Inhibitors) illustrates the evolving therapeutic preferences and strategies utilized in managing BPH.

### By Therapy: Mono Drug Therapy (Largest) vs. Combination Drug Therapy (Fastest-Growing)

The US benign prostatic-hyperplasia-treatment market exhibits a notable division between Mono Drug Therapy and Combination Drug Therapy. Mono Drug Therapy currently holds a significant portion of the market share, being the preferred choice among practitioners due to its simplicity and effectiveness. In contrast, Combination Drug Therapy, while smaller in market share, is rapidly gaining traction as clinical evidence supports its effectiveness in treating patients with more complex conditions. 

Recent trends indicate that the demand for Combination Drug Therapy is increasing, driven by the need for personalized and more effective treatment options. Factors such as an aging population, rising prevalence of benign prostatic hyperplasia, and advancements in pharmaceutical research contribute to the rapid growth of this segment. Healthcare providers are increasingly recognizing the efficacy of combination therapies, leading to a shift in treatment paradigms that favor bespoke patient care.

Mono Drug Therapy: Dominant vs. Combination Drug Therapy: Emerging

Mono Drug Therapy is the dominant approach within the US benign prostatic-hyperplasia-treatment market, characterized by its efficacy and simplicity, making it a standard choice for initial treatment. This segment is particularly favored for its ease of administration and well-established safety profile. On the other hand, Combination Drug Therapy represents an emerging segment that is becoming increasingly relevant as clinicians look to optimize treatment outcomes. This approach combines multiple medications to address varied symptoms and patient-specific needs, thereby increasing effectiveness. With healthcare trends leaning towards personalized medicine, Combination Drug Therapy is experiencing rapid adoption, showcasing its potential to redefine treatment standards in the market.

## Competitive Benchmarking

The benign prostatic hyperplasia treatment market is characterized by a dynamic competitive landscape, driven by an increasing prevalence of the condition among aging populations and a growing demand for effective therapeutic options. Key players such as Astellas Pharma (JP), Eli Lilly and Company (US), and Johnson & Johnson (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Astellas Pharma (JP) focuses on developing advanced pharmacological solutions, while Eli Lilly and Company (US) emphasizes a robust pipeline of novel therapies. Johnson & Johnson (US) is actively pursuing mergers and acquisitions to expand its portfolio, indicating a trend towards consolidation in the market.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive innovation and set industry standards, thereby shaping the competitive environment.
In October Astellas Pharma (JP) announced a strategic partnership with a leading biotechnology firm to co-develop a new class of medications targeting benign prostatic hyperplasia. This collaboration is expected to accelerate the development timeline and enhance the therapeutic options available to patients, reflecting Astellas' commitment to innovation and patient-centric solutions. The partnership may also strengthen Astellas' position in the market by diversifying its product offerings.
In September Eli Lilly and Company (US) launched a new digital health platform aimed at improving patient engagement and adherence to treatment regimens for benign prostatic hyperplasia. This initiative underscores the company's focus on integrating technology into its therapeutic approach, potentially leading to better patient outcomes and increased market share. The platform may serve as a differentiator in a competitive landscape increasingly focused on patient-centric solutions.
In August Johnson & Johnson (US) completed the acquisition of a smaller pharmaceutical company specializing in urology treatments, further expanding its portfolio in the benign prostatic hyperplasia space. This acquisition is likely to enhance Johnson & Johnson's capabilities in research and development, allowing for a more comprehensive approach to treatment options. The move reflects a broader trend of consolidation in the industry, as larger firms seek to bolster their offerings through strategic acquisitions.
As of November current competitive trends in the benign prostatic hyperplasia treatment market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the importance of developing unique therapeutic solutions and enhancing operational efficiencies.

## Recent News & Developments

Recent developments in the US Benign Prostatic Hyperplasia Treatment Market have shown significant activity among key players, with companies like Merck and Co., Novartis, and Eli Lilly advancing their treatment options. In September 2023, Bausch Health announced the launch of a new formulation designed to improve patient outcomes, which is expected to enhance their market share. The growing prevalence of BPH in the aging US population has driven demand, prompting Boehringer Ingelheim and Ferring Pharmaceuticals to invest in Research and Development for innovative therapies.

Furthermore, in August 2023, AbbVie completed the acquisition of a smaller biotech company focused on novel BPH treatments, aiming to expand its product portfolio substantially. Companies such as Astellas Pharma and Sanofi continue to explore strategic partnerships to enhance their treatment offerings. Over the past few years, there has been a consistent upward trend in the market valuation of companies like Johnson and Johnson and Teva Pharmaceuticals, contributing positively to the overall market dynamics. The US government has also identified BPH as a priority area for research funding, underlining its significance in public health initiatives.

The ongoing advancements and investments clearly indicate a vigorous market evolution in the US.

## Report Scope

| MARKET SIZE 2024 | 2632.61(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2772.66(USD Million) |
| MARKET SIZE 2035 | 4657.5(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.32% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Astellas Pharma (JP), Boehringer Ingelheim (DE), Eli Lilly and Company (US), GlaxoSmithKline (GB), Johnson & Johnson (US), Merck & Co. (US), Pfizer (US), Sanofi (FR), Teva Pharmaceutical Industries (IL) |
| Segments Covered | Therapeutic Class, Therapy |
| Key Market Opportunities | Emergence of minimally invasive therapies enhances patient outcomes in the benign prostatic-hyperplasia-treatment market. |
| Key Market Dynamics | Rising demand for minimally invasive procedures drives innovation in benign prostatic hyperplasia treatment options. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US benign prostatic-hyperplasia-treatment market in 2024?**
A: The market valuation was $2632.61 Million in 2024.

**Q: What is the projected market valuation for the US benign prostatic-hyperplasia-treatment market by 2035?**
A: The projected valuation for 2035 is $4657.5 Million.

**Q: What is the expected CAGR for the US benign prostatic-hyperplasia-treatment market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 5.32%.

**Q: Which therapeutic class generated the highest revenue in the US benign prostatic-hyperplasia-treatment market?**
A: The 'Others' segment generated the highest revenue, with a valuation of $1053.05 Million in 2024.

**Q: What are the two main types of drug therapies in the US benign prostatic-hyperplasia-treatment market?**
A: The two main types of drug therapies are Mono Drug Therapy and Combination Drug Therapy.

**Q: What was the revenue for Mono Drug Therapy in 2024?**
A: The revenue for Mono Drug Therapy was $1580.0 Million in 2024.

**Q: How much revenue is projected for Combination Drug Therapy by 2035?**
A: The revenue for Combination Drug Therapy is projected to reach $1897.5 Million by 2035.

**Q: Which companies are considered key players in the US benign prostatic-hyperplasia-treatment market?**
A: Key players include Astellas Pharma, Boehringer Ingelheim, Eli Lilly and Company, and others.

**Q: What was the revenue generated by 5-Alpha Reductase Inhibitors in 2024?**
A: The revenue generated by 5-Alpha Reductase Inhibitors was $526.52 Million in 2024.

**Q: What is the projected growth trend for the US benign prostatic-hyperplasia-treatment market?**
A: The market is expected to grow steadily, reaching $4657.5 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-benign-prostatic-hyperplasia-treatment-market-15866*